2005 Distinguished Achievement Award: Timothy Scott

// Chemical & Biological Engineering

Tags: alumni, CBE E-Day, Engineers' Day, Timothy Scott

Share this story:

Timothy C. Scott
President
Provectus Pharmaceuticals, Inc.
PhDCBE ’85
Knoxville, TN

 A self-described “lab brat,” Timothy C. Scott grew up “helping” his father conduct experiments at Oak Ridge National Laboratory (ORNL) on the weekends. As a research engineer, his father reached the level of senior corporate fellow and is a member of the National Academy of Engineering.

It’s no wonder then, that Scott chose engineering as a profession or that he excelled as a high school student and was the top college of engineering graduate from the University of Tennessee, Knoxville.

Scott participated in the engineering co-op program at ORNL and completed his PhD in chemical engineering at UW-Madison in 1985. Like his father, he first worked as a research engineer with the national lab. He quickly rose to senior positions and was named director of ORNL’s Bioprocessing R&D Center. He achieved national recognition for the use of advanced biotechnology in the production of energy, fuels and chemicals. In addition, he has conducted research in areas involving effects of electromagnetic fields on multiphase systems, separations science, materials science, nuclear technology, laser systems and medical applications.

In November of 1985, Scott took advantage of an entrepreneurial leave program and joined a team in forming Genase, LLC, a company that produces industrial enzymes using technology Scott helped develop at ORNL.

Rather than return to ORNL, he remained in private industry and was a member of the founding team of Photogen Technologies. Scott helped to found a total of eight companies, seven of which went public.

Currently, Scott serves as president and director of Provectus Pharmaceuticals, Inc. The corporation has four subsidiaries involved in oncology, dermatology, biotechnology, laser systems and over-the-counter products. Scott is co-inventor of Provectus’ flagship drugs Xantryl and Provecta which are currently in clinical trials for psoriasis, melanoma and breast cancer.

Scott holds 17 U.S. patents and has published more than 70 peer-reviewed papers. Several of his innovations have been licensed to the oil, gas and biotechnology industries.

He received the R&D 100 Award for creating a new industrial enzyme, the National Laboratory Consortium Award for Excellence in Technology Transfer, the Inventor’s Forum Advanced Technology Award and the Martin Marietta Energy Systems Inventor of the Year Award. He also has been an adjunct associate professor of chemical engineering at the University of Tennessee, Knoxville, while advising successful PhD and MS degree candidates in chemical engineering.